Veradigm Inc.

MDRX

$4.81

+0.19%

2026-09-04 11:52:49 EDT+$0.01

Healthcare

Medical - Healthcare Information Services

OTC

Active Trading

Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, ...

Price Action of MDRX

$4.81

+0.19%+$0.01

High—

Low—

52W High-19.8%

Rel. vol—

Interval

Range54m

Volume—SMA5SMA10

—

Veradigm Inc., headquartered in Chicago, Illinois, is a prominent healthcare technology company that rebranded from Allscripts Healthcare Solutions in 2023. The company operates at the intersection of clinical care and data analytics, delivering platforms designed to improve healthcare efficiency and reduce costs. Its business model is built around a robust ...Veradigm Inc., headquartered in Chicago, Illinois, is a prominent healthcare technology company that rebranded from Allscripts Healthcare Solutions in 2023. The company operates at the intersection of clinical care and data analytics, delivering platforms designed to improve healthcare efficiency and reduce costs. Its business model is built around a robust ecosystem of connectivity and data exchange, serving a diverse client base that includes physician practices, hospitals, health plans, and biopharmaceutical enterprises. Product and Service Offerings: The company’s portfolio is extensive, spanning EHR solutions like Veradigm EHR and Practice Fusion EHR, which are tailored for small to mid-sized practices. Their financial technology suite, notably the Veradigm Payerpath platform, provides revenue cycle management, clearinghouse services, and AI-driven scheduling tools that assist providers in optimizing their financial performance. For payers and life sciences firms, Veradigm leverages its proprietary health datasets to provide risk adjustment analytics, quality management tools, and real-world evidence platforms, which are critical for clinical research and pharmaceutical market strategy. Financial and Operational Context: As of the latest trailing twelve-month (TTM) reporting, Veradigm operates with a focus on enterprise-level data integration. The company maintains a strong liquidity position with a current ratio of 2.95, though it faces challenges with profitability, reflected in a negative net profit margin of -14.7%. The firm has invested heavily in research and development (16.6% of revenue) and sales and administrative operations (28.8% of revenue) to maintain its competitive edge in the highly fragmented healthcare IT market. The enterprise value is approximately $588 million, reflecting its current market position as a mid-cap technology player. Strategic Outlook: Under the leadership of CEO Don Trigg, the company is tasked with navigating a complex healthcare regulatory environment while modernizing its legacy systems. The firm’s long-term success hinges on its ability to monetize its massive clinical data assets through AI-driven applications and improved payer-provider connectivity. By shifting its focus from traditional software delivery to high-value data insights, Veradigm aims to address the rising operational costs in healthcare, positioning itself as a vital infrastructure partner for the next generation of digital health.ExpandCollapse

Founded

1986

Employees

2300

CEO

Donald D. Trigg

Full Name

Veradigm Inc.

Sector

Healthcare

Industry

Medical - Healthcare Information Services

ROE

-7.13%

Market Cap

$0.52B

Current Ratio

2.95

WACC

5.77%

ROIC

3.42%

Contact Information

https://veradigm.com

800 334 8534

222 Merchandise Mart Plaza, Chicago, IL 60654

Key Metrics of MDRX

Snapshot

Latest / TTM · 3 periods

Market Cap

$524.25M

ROCE

-2.1%

EV / EBITDA

10.09x

+0.0% YoY

FCF Yield

10.2%

+6.5% YoY

Cash Conversion Cycle

68.8d

Current Ratio

2.95

Quick take

TTM —

Positive CCC

Financial Highlights of MDRX

Profitability trend

Latest / TTM · 3 periods

Gross Margin

52.5%

Net Margin

-14.7%

P/E Ratio

-7.18x

n/a

Debt / Equity

0.22

n/a

Current Ratio

2.95

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of MDRX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $0.08 · Revenue $144.10M · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $0.12 · Revenue $150.80M · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $0.30 · Revenue $583.20M · 1 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $0.07 · Revenue $149.00M · 1 analysts

Recent history

Jun 26, 2026
8-K · SEC filing
View filing
May 26, 2026
10-K · SEC filing
View filing
Apr 6, 2026
8-K · SEC filing
View filing
Feb 24, 2026
8-K · SEC filing
View filing
Feb 17, 2026
8-K · SEC filing
View filing
Mar 18, 2025
FY2022 · Annual results
EPS $-0.67 · Revenue $588.02M
View filing

Financial Statements of MDRX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$588.0M	+1.8%	+0.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-86.5M	-164.3%	+114.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+52.5%	+17.3%	+4.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-4.6%	-135.2%	+563.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-14.7%	-163.2%	+114.5%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$83.3M	+206.1%	-2.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+14.2%	+204.2%	-2.6%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	21.6%	-18.6%	+1.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.95x	+89.3%	-0.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$1.5B	-38.0%	-1.4%

Actual vs Estimate

A Dec 30Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.67 vs 0.80	-184.0%	0.12 vs 0.05	+140.0%
Revenue Surprise	$588.0M vs $614.5M	-4.3%	$151.9M vs $144.6M	+5.1%

Insider Transactions of MDRX

Acquisitions (A)

Since Nov 3, 2025

Disposals (D)

Since Nov 3, 2025

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 1, 2026	Sacks Jonathan S	director, 10 percent owner:	Common Stock, par value $0.01 per share	A	42,507	—
Jun 1, 2026	STONEHILL CAPITAL MANAGEMENT LLC	director, 10 percent owner:	Common Stock, par value $0.01 per share	A	42,507	—
May 27, 2026	Greyenbuhl Christian	officer: Chief Financial Officer	Common Stock	—	0	—
May 10, 2026	Jacobson Eric L	officer: SVP Interim General Counsel	Common Stock	D	1,584	$4.46
May 1, 2026	Jacobson Eric L	officer: SVP Interim General Counsel	Common Stock	A	75,000	—

Earnings Call Transcript of MDRX

1 transcript segments

Q3 2022

Unknown Speaker

Operator: Greetings, and welcome to Allscripts' Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Jenny Gelinas. Thank you. You may begin. Jenny Gelinas : Thank you very much. Good afternoon, and welcome to the Allscripts Third Quarter 2022 Earnings Conference Call. Our speakers today are Rick Poulton, Allscripts' Chief Executive Officer; Tom Langan, President and Chief Commercial Officer; and Leah Jones, our Chief Financial Officer. We will be making a number of forward-looking statements during the presentation and the Q&A part of the call. These statements are based on current expectations and involve a number of risks and uncertainties that could cause our actual results to vary materially. We undertake no obligation to revise these forward-looking statements in light of new information or future events. Please refer to our earnings release and SEC filings for more information regarding the risk factors that may affect our results. Please reference the GAAP and non-GAAP financial statements as well as the non-GAAP tables in our earnings release that are available on our Investor Relations website. And with that, I'm going to hand the call over to Rick. Richard Poulton : Okay. Thanks, Jenny, and thanks, everybody, for joining us on our third quarter call today. 5 weeks ago we hosted our Investor Day in New York City. I know many of you were able to join us either in person or virtually and heard directly from key members of our leadership team our strategy for creating value across our 3-sided network of providers, payers and life sciences clients. For those of you who were unable to participate, I do encourage you to view the webcast, which can still be accessed on our Investor Relations website. . Over the course of that presentation, we laid out our business strategies in great detail, so I'll keep my prepared remarks, particularly brief today and just share a few thoughts on what I think investors and analysts should be focused on as they digest our third quarter results. First, our team executed fabulously during the quarter. Our business continues to generate meaningful top line growth, 25-plus percent EBITDA margins and free cash flow conversion year-to-date of more than 20%. In terms of momentum, both gross profit and adjusted EBITDA margins expanded meaningfully on a year-over-year basis as well as sequentially from the second quarter. And our $34 million of free cash flow during the quarter brought our year-to-date total over $90 million, as far as we know, the highest of any company in health care services with an enterprise value below $2.5 billion. We are proud of the fact that we laid out ambitious financial goals early this year, have maintained them all year long despite some bleak macroeconomic overhang, and are delivering results consistent with those goals through the first 9 months of the year. …

Leadership Team of MDRX

15 executives

Name	Title	Compensation	Gender	Year Born	Status
Donald D. Trigg	Chief Executive Officer & Director	USD 2,446,447	Male	1972	Active
Tally Baker	Chief Human Resources Officer	USD 472,983	Female	1982	Active
Dave Dornstreich	Vice President Strategic Initiatives & Data Partnerships of Payer and Life Sciences Division	USD 83,000	Male	—	Active
Eric Jacobson	Senior VP, Interim General Counsel & Corporate Secretary	—	Male	1976	Active
Stella Chang	Executive Director of Payer & Life Sciences Division	—	Female	—	Active
Christian Greyenbuhl	Chief Financial Officer	—	Male	—	Active
Elliot Bryant	Senior Vice President & General Manager for Classic Client Solutions Business Unit	—	Male	—	Active
John Sage	Senior Vice President of U.S. Hospitals & Health Systems Sales	—	Male	—	Active
Troy Tetzlaff	Senior Vice President of Revenue Operations	—	Male	—	Active
Alan Fowles	President of Allscripts International	—	Male	—	Active
Steven Paul Halper	Vice President of Investor Relations	—	Male	—	Active
Divesh Singla	Managing Director of India Operations	—	Male	—	Active
John Mayr	Senior Vice President of Global Client Delivery Organization	—	Male	—	Active
Richard Elmore	Senior Vice President of Corporate Development & Strategy	—	Male	—	Active
Tehsin Syed	Chief Product & Technology Officer	—	Male	1977	Active

Recent News of MDRX

Seeking Alpha5/28/2026Neutral

Veradigm Inc. (MDRX) Discusses Progress on SEC Filings, Relisting Efforts and Strategic Update Transcript

Business Wire5/26/2026Neutral

Veradigm Files 2023 and 2024 Form 10-K

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today the filing of its comprehensive Annual Report on Form 10-K for the years ended December 31, 2023 and 2024 (the “2023 and 2024 Form 10-K”) with the Securities and Exchange Commission (“SEC”). “In our previous shareholder update, I framed a critical must-do to get current and stay current on our SEC filings. Today marks a major milestone in tha.

Business Wire5/6/2026Neutral

Veradigm Survey: Independent Practices Rely on Technology to Stay Independent

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today released findings from a nationally distributed survey of 360 independent practice leaders, conducted in March 2026. The survey respondents resolved to remain independent and are counting on technology as a critical lever to drive practice performance. Technology Is Critical to Support Independent Practice Growth The survey found that despite real and.

Historical Employee Count of MDRX

Current

2,300

Change

+121.79%

Minimum

1,037

Maximum

8,000

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2024	2,300	10-K	May 26, 2026	View
Dec 31, 2022	1,037	10-K	Mar 18, 2025	View
Dec 31, 2021	8,000	10-K	Feb 25, 2022	View

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Veradigm Inc.

Contact Information

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

8-K · SEC filing

10-K · SEC filing

8-K · SEC filing

8-K · SEC filing

8-K · SEC filing

FY2022 · Annual results

Veradigm Inc. (MDRX) Discusses Progress on SEC Filings, Relisting Efforts and Strategic Update Transcript

Veradigm Files 2023 and 2024 Form 10-K

Veradigm Survey: Independent Practices Rely on Technology to Stay Independent

Recent Filings

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

8-K · SEC filing

10-K · SEC filing

8-K · SEC filing

8-K · SEC filing

8-K · SEC filing

FY2022 · Annual results

Veradigm Inc. (MDRX) Discusses Progress on SEC Filings, Relisting Efforts and Strategic Update Transcript

Veradigm Files 2023 and 2024 Form 10-K

Veradigm Survey: Independent Practices Rely on Technology to Stay Independent

Recent Filings